Agile Therapeutics (AGRX) Scheduled to Post Quarterly Earnings on Thursday

Agile Therapeutics (NASDAQ:AGRXGet Rating) is scheduled to be announcing its earnings results after the market closes on Thursday, August 11th. Individual that are interested in registering for the company’s earnings conference call can do so using this link.

Agile Therapeutics (NASDAQ:AGRXGet Rating) last released its earnings results on Thursday, May 12th. The specialty pharmaceutical company reported ($3.78) earnings per share for the quarter. Agile Therapeutics had a negative return on equity of 599.24% and a negative net margin of 1,209.95%. The business had revenue of $1.76 million during the quarter. On average, analysts expect Agile Therapeutics to post $-2 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Agile Therapeutics Price Performance

AGRX opened at $0.57 on Thursday. The company’s 50 day simple moving average is $0.97 and its two-hundred day simple moving average is $6.81. Agile Therapeutics has a 1-year low of $0.49 and a 1-year high of $50.40. The firm has a market capitalization of $2.57 million, a price-to-earnings ratio of -0.02 and a beta of 1.22.

Wall Street Analyst Weigh In

AGRX has been the topic of several analyst reports. Maxim Group raised shares of Agile Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, July 26th. StockNews.com initiated coverage on shares of Agile Therapeutics in a research report on Wednesday. They set a “sell” rating on the stock.

Institutional Trading of Agile Therapeutics

An institutional investor recently raised its position in Agile Therapeutics stock. Renaissance Technologies LLC grew its holdings in Agile Therapeutics, Inc. (NASDAQ:AGRXGet Rating) by 281.3% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 621,200 shares of the specialty pharmaceutical company’s stock after acquiring an additional 458,300 shares during the period. Renaissance Technologies LLC owned about 16.94% of Agile Therapeutics worth $130,000 as of its most recent filing with the Securities & Exchange Commission. 27.96% of the stock is owned by hedge funds and other institutional investors.

Agile Therapeutics Company Profile

(Get Rating)

Agile Therapeutics, Inc, a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen.

See Also

Earnings History for Agile Therapeutics (NASDAQ:AGRX)

Want More Great Investing Ideas?

Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.